Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Noonan Syndrome 1Neoplasms 1Melanoma 1Intestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1EGFR-mutant Non-small Cell Lung Cancer 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ductal 1Bronchial Neoplasms 1Breast Neoplasms 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Irinotecan 8Bevacizumab 8Fluorouracil 7Leucovorin 6Oxaliplatin 5Capecitabine 4Drug Therapy 3Cetuximab 35,10-methylenetetrahydrofolic acid 3Radiotherapy 2Levoleucovorin 2Folfox protocol 2Colonoscopy 2Bisacodyl 2Aspirin 2Artesunate 2trametinib 1spartalizumab 1repotrectinib 1pralsetinib 1pembrolizumab 1nazartinib 1napabucasin 1lutetium Lu 177 dotatate 1guadecitabine 1encorafenib 1copper dotatate CU-64 1canakinumab 1camrelizumab 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Intestinal Neoplasms × nazartinib × Clear all
NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔